Table 2 Efficacy of monoclonal antibodies against CGRP or the CGRP receptor in the therapy of MOH
From: Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline
Drug | Dose | Reduction of migraine days/month | 50%-responder rate for migraine days (%) |
|---|---|---|---|
Fremanezumab | 1 × Quarterly | − 4.7 | 35 |
Fremanezumab | 1 × Monthly | − 5.2 | 39 |
Placebo |  | − 2.5 | 14 |
Erenumab | 70 mg | − 6.6 | 36 |
Erenumab | 140 mg | − 6.6 | 35 |
Placebo |  | − 3.5 | 18 |
Galcanezumab | 120 mg | − 4.8 | 28 |
Galcanezumab | 240 mg | − 4.5 | 28 |
Placebo |  | − 2.2 | 15 |
Eptinezumab | 100 mg | − 8.4 | 60 |
Eptinezumab | 300 mg | − 8.6 | 62 |
Placebo |  | − 3.0 | 14 |